EIF5A2 and non-small cell lung carcinoma: Furthermore, it has been shown that knockdown of eIF5A2 enhances NSCLC sensitivity to cisplatin by preventing epithelial–mesenchymal transition (EMT), reducing the migration and invasive capabilities of NSCLC cells [35].